PARP1-Selective Inhibitor Compounds for HRD Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need for PARP inhibitors with improved selectivity for PARP1 to enhance efficacy and reduce toxicity in cancer treatment, particularly for tumors with homologous recombination deficiency (HRD).
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salts, stereoisomers, and solvates, which selectively inhibit PARP1, potentially trapping it on DNA to induce DNA double strand breaks, thereby selectively killing cancer cells with HRD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are used to treat cancer, then efficacy against tumors with HRD is improved, but toxicity increases
Solution Approach 1:
The patent applies local quality by designing the compound to selectively target PARP1 over PARP2 through specific molecular interactions. The compound structure (Formula I) is optimized to bind preferentially to PARP1's catalytic domain, creating localized selective inhibition that spares other PARP family members and reduces off-target toxicity while maintaining efficacy against HRD tumors.
Solution Approach 2:
The patent segments the PARP inhibition function by developing compounds that specifically inhibit PARP1 while leaving PARP2 relatively unaffected. This segmentation allows selective targeting of the PARP1 pathway in HRD tumors, achieving therapeutic efficacy while reducing the toxicity associated with broad-spectrum PARP inhibition.
2Reliability
If selectivity for PARP1 is improved, then efficacy is enhanced, but device complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical parameters of the compound structure (Formula I), including substituent groups at specific positions (R1-R6, X, Y, Z, n), to optimize selectivity for PARP1. By adjusting these molecular parameters, the compound achieves enhanced selectivity through improved binding affinity and specificity for PARP1's unique structural features.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituent patterns at key positions in the molecule that locally enhance interaction with PARP1's active site. This localized optimization of molecular properties achieves high selectivity without requiring complex overall molecular architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively treats cancers with BRCA1/2 mutations or HRD by enhancing cell death and limiting tumor growth with reduced toxicity.
Implementation Method 1
selectively inhibit PARP1, potentially trapping it on DNA to induce DNA double strand breaks
Data Source
AI summary
Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.